, Tracking Stock Market Picks
Enter Symbol:
Sinovac Biotech, Ltd. (SVA) [hlAlert]

up 19.60 %

Sinovac Biotech, Ltd. (SVA) rated Buy with price target $10 by Aegis Capital

Posted on: Friday,  Aug 15, 2014  12:00 AM ET by Aegis Capital

Aegis Capital rated Buy Sinovac Biotech, Ltd. (NASDAQ: SVA) on 08/15/2014. Previously Aegis Capital rated Buy Sinovac Biotech, Ltd. (NASDAQ: SVA) on
08/15/2013., when the stock price was $4.54. Since then, Sinovac Biotech, Ltd. has gained 19.60% as of 09/17/2015's recent price of $5.43.
If you would have followed the previous Aegis Capital's recommendation on SVA, you would have gained 19.6% of your investment in 763 days.

Sinovac Biotech Ltd. is a holding company that conducts its business in China, through its 71.56%-owned subsidiary, Sinovac Beijing, and its wholly owned subsidiaries, Tangshan Yian and Sinovac Hong Kong. It is an integrated biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. The Company?s portfolio of products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. Its Panflu vaccine is available in China against the H5N1 influenza virus. Its pipeline consists of vaccine candidates in the pre-clinical and clinical development phases in China, including human vaccines for the EV71, Japanese encephalitis and rabies in pre-clinical development, a vaccine for the severe acute respiratory syndrome (SARS) virus that has completed a Phase I clinical trial and a split viron vaccine for the H5N1 influenza virus that has completed a Phase II clinical trial.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/15/2014 12:00 AM Buy
5.61 10.00
as of 10/17/2014
1 Week up  3.74 %
1 Month up  4.56 %
3 Months down  -3.12 %
1 YTD down  -13.88 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/15/2013 9:25 AM Buy
4.54 7.00
12/12/2012 8:25 AM Hold
2.51 2.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy